Skip to main content
Quest Diagnostics

Diffusion MRI Relates to Plasma Aβ42/40 in PET Negative Participants Without Dementia

Diffusion MRI Relates to Plasma Aβ42/40 in PET Negative Participants Without Dementi

Authors: DeSimone JC, Wang WE, Loewenstein DA, Duara R, Smith GE, McFarland KN, Armstrong MJ, Weber DM, Barker W, Coombes SA, Vaillancourt DE

Citation: Alzheimers Dement. 2024 Mar 5. doi: 10.1002/alz.13693.

Specialties: Neurology

Related content

Publication
Clinical Utility of Plasma Aβ42/40 Ratio by LC-MS/MS in Alzheimer’s Disease Assessment
On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
Conference Presentation
The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.